ImmuCell outlines cautious H2 outlook as capacity expansion supports First Defense suite
Source: SeekingAlpha
2025-08-15 11:04:43 ET
More on ImmuCell
- ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript
- Financial information for ImmuCell
Read the full article on Seeking Alpha
For further details see:
ImmuCell outlines cautious H2 outlook as capacity expansion supports First Defense suite
ImmuCell Corporation
NASDAQ: ICCC
ICCC Trading
1.39% G/L:
$6.58 Last:
7,550 Volume:
$6.39 Open:
ICCC Latest News
March 04, 2026 04:05:00 pm
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
February 18, 2026 08:37:10 am
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
January 08, 2026 04:05:00 pm
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
January 07, 2026 08:10:57 am
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
ICCC Stock Data
$60,757,363
6,377,325
3.65%
14
N/A
Biotechnology & Life Sciences
Healthcare
US
Portland
